News & Updates

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.